There has been a steady stream of China healthcare IPOs - most of them drug developers - on the domestic, Hong Kong and US bourses in recent months. They might be benefiting from a COVID-19 tailwind but it won't be permanent
Two months ago, Akeso Biopharma became the eighth Chinese private equity-backed healthcare company to go public since the start of the year. At a time when the general IPO market was exhibiting volatile...
Meishubao, China’s leading online art education platform, has raised $40 million in an extended Series C round led by Tencent Holdings.
Kuaidian, a Chinese interactive content provider, has raised close to $100 million in Series C funding led by Sequoia Capital China. Existing investors GGV Capital and Morningside Venture Capital re-upped.
Warburg Pincus will sell an approximately 5.5% interest in Hong Kong-listed IVF services provider Jinxin Fertility for about HK$1.5 billion ($194 million) through a share placement.
CLSA, the international arm of China-based brokerage CITIC Securities, has launched a strategy to offer high net worth clients investment opportunities in late-stage private companies in Asia.